Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ipca LaboratoriesNSE:IPCALAB +0.64%91 Debt-to-EBITDA is 0.38 as of Mar. 2026, which is 48% below its 10-year median of 0.73. GuruFocus rates NSE:IPCALAB with a GF Score™ of 91/100 and a GF Value™ of ₹1,601.78 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Ipca Laboratories ranks better than 75.22% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ipca Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:IPCALAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.17 Med: 0.73 Max: 1.57
Current: 0.39
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ipca Laboratories was 1.57. The lowest was 0.17. And the median was 0.73.
NSE:IPCALAB's Debt-to-EBITDA is ranked better than 75.22% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs NSE:IPCALAB: 0.39
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ipca Laboratories Debt-to-EBITDA Related Terms
Ipca Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Ipca Laboratories (NSE:IPCALAB) has a Debt-to-EBITDA of 0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ipca Laboratories. This is 48% below median its historical median of 0.73. Over the past decade, Ipca Laboratories' Debt-to-EBITDA has ranged from 0.17 to 1.57. According to the industry distribution chart, Ipca Laboratories ranks #171 out of 690 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Ipca Laboratories' Debt-to-EBITDA too high?
Ipca Laboratories' current Debt-to-EBITDA of 0.38 is 48% below median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 1.57. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Ipca Laboratories' value of 0.38 is 76.8% below this industry median. Based on the distribution chart, Ipca Laboratories ranks #171 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ipca Laboratories has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #171 out of 690 companies for Debt-to-EBITDA. This places Ipca Laboratories in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Ipca Laboratories' value of 0.38 is 76.8% below this benchmark. Historically, Ipca Laboratories' own Debt-to-EBITDA has ranged from 0.17 to 1.57 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 1.64, Ipca Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current Debt-to-EBITDA of 0.38 is 76.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ipca Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current Debt-to-EBITDA is 0.38, which is 48% below median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,601.78, compared to a current price of ₹1,789.00 — trading 11.7% above its estimated fair value. The current Debt-to-EBITDA is 0.38, which is 48% below median its 10-year median of 0.73 and 76.8% below the Drug Manufacturers industry median of 1.64. Ipca Laboratories' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,789.00 is trading 11.7% above its estimated GF Value™ of ₹1,601.78.
GuruFocus considers Ipca Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:IPCALAB:
Debt-to-EBITDA: 0.38 (48% below median its 10-year median of 0.73)
GF Value™: ₹1,601.78 vs. price of ₹1,789.00 (11.7% above fair value)
Industry Position: 76.8% below the Drug Manufacturers median (#171 of 690)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
91GF Score
Get the complete analysis for NSE:IPCALAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
